Literature DB >> 15805296

Sensitivity of undifferentiated, high-TCR density CD8+ cells to methylene groups appended to tumor antigen determines their differentiation or death.

Kouichiro Kawano1, Clay L Efferson, George E Peoples, Darrick Carter, Naotake Tsuda, James L Murray, Constantin G Ioannides.   

Abstract

CD8(+) cells expressing high numbers of TCR per cell (TCR(hi)) are considered important mediators of antitumor effects. To understand the relationship between TCR density and antigen affinity for TCR in the outcome of stimulation with antigen and differentiation of CTL recognizing tumor antigen, we analyzed perforin induction in ovarian tumor-associated lymphocytes in response to the smallest possible changes in the atomic forces of interaction between antigen and TCR. Stimulating undifferentiated, apoptosis-resistant CD8(+) cells expressing high levels of E75-TCR (TCR(hi)) with variants of the CTL epitope E75, HER-2 (369-377), induced their stepwise differentiation, first to IFN-gamma(+) Perf(-) and to TCR(hi) IFN-gamma(+) Perf(+) cells. Blocking caspase-9 activation at antigen stimulation also enhanced the generation of TCR(hi) Perf(hi) cells, demonstrating that TCR density dictated the pathway of death activated by stimulation with the same agonist. Expansion and differentiation of TCR(hi) Perf(+) CTL required an agonist of optimal CH(2) side chain length, which in this study was equal to two CH(2) groups appended to E75 at the Gly(4) position. Side chains one CH(2) shorter or longer than optimal were either less stimulatory or induced death of TCR(hi) Perf(+) cells. Differentiation of TCR(hi) CD8(+) cells can be finely tuned by synthetic amino acids in the peptide, whose side chains induce small increments in the affinity of the antigen for TCR below the affinity which induce apoptosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15805296     DOI: 10.1158/0008-5472.CAN-04-2232

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Created Gli-1 duplex short-RNA (i-Gli-RNA) eliminates CD44 Hi progenitors of taxol-resistant ovarian cancer cells.

Authors:  Takashi Mine; Satoko Matsueda; Hui Gao; Yufeng Li; Kwong-Kwok Wong; George E Peoples; Soldano Ferrone; Constantin G Ioannides
Journal:  Oncol Rep       Date:  2010-06       Impact factor: 3.906

2.  Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells.

Authors:  Takashi Mine; Satoko Matsueda; Yufeng Li; Hiroshi Tokumitsu; Hui Gao; Cristopher Danes; Kwong-Kwok Wong; Xinhui Wang; Soldano Ferrone; Constantin G Ioannides
Journal:  Cancer Immunol Immunother       Date:  2008-12-02       Impact factor: 6.968

3.  Evaluation of Attenuated Tumor Antigens and the Implications for Peptide-Based Cancer Vaccine Development.

Authors:  J S Berry; T J Vreeland; D F Hale; D O Jackson; A F Trappey; J M Greene; M O Hardin; G S Herbert; G T Clifton; G E Peoples
Journal:  J Cancer       Date:  2017-05-11       Impact factor: 4.207

4.  Inhibition of GSK3 and MEK induced cancer stem cell generation via the Wnt and MEK signaling pathways.

Authors:  Shengtao Liao; Li Gan; Wanxiang Qin; Chang Liu; Zhechuan Mei
Journal:  Oncol Rep       Date:  2018-07-25       Impact factor: 3.906

5.  Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients.

Authors:  Tommy A Brown; Kevin Byrd; Timothy J Vreeland; Guy T Clifton; Doreen O Jackson; Diane F Hale; Garth S Herbert; John W Myers; Julia M Greene; John S Berry; Jonathan Martin; John C Elkas; Thomas P Conrads; Kathleen M Darcy; Chad A Hamilton; George L Maxwel; George E Peoples
Journal:  Cancer Med       Date:  2019-07-05       Impact factor: 4.452

6.  Integrity of plasma DNA is inversely correlated with vaccine-induced antitumor immunity in ovarian cancer patients.

Authors:  Kayoko Waki; Kanako Yokomizo; Kouichiro Kawano; Naotake Tsuda; Nobukazu Komatsu; Akira Yamada
Journal:  Cancer Immunol Immunother       Date:  2020-05-11       Impact factor: 6.968

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.